% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Mair:1053910,
      author       = {Mair, Maximilian J and Lohmann, Philipp and Galldiks,
                      Norbert and Belting, Mattias and Brandal, Petter and Broen,
                      Martinus P G and Cicone, Francesco and Daisne,
                      Jean-François and Ducray, François and Ehret, Felix and
                      Furtner, Julia and Jakola, Asgeir S and Niyazi, Maximilian
                      and Pellerino, Alessia and Rasschaert, Marika and Razis,
                      Evangelia and Sahm, Felix and Smits, Marion and Tolboom,
                      Nelleke and Verger, Antoine and Le Rhun, Emilie and Minniti,
                      Giuseppe and Weller, Michael and Preusser, Matthias and
                      Albert, Nathalie L},
      title        = {{IMG}-82. {P}ositron emission tomography ({PET}) use among
                      {E}uropean {O}rganisation for {R}esearch and {T}reatment of
                      {C}ancer – {B}rain {T}umour {G}roup ({EORTC}-{BTG}) sites
                      – a cross-sectional survey},
      issn         = {1523-5866},
      reportid     = {FZJ-2026-01608},
      year         = {2025},
      abstract     = {AbstractBACKGROUNDPositron emission tomography (PET) is
                      increasingly used in patients with brain tumors, yet its
                      adoption varies across institutions.METHODSTo assess the
                      current landscape, a cross-sectional survey was conducted
                      among European Organization for Research and Treatment of
                      Cancer (EORTC) – Brain Tumour Group (BTG) sites between
                      June 2024 and August 2024.RESULTSOut of the 312 sites
                      invited, 103 replies from 20 countries in the Europe/Middle
                      East region were received. PET availability was reported by
                      96/103 $(93.2\%)$ sites, of whom 74 reported PET use in
                      patients with brain tumors. Most frequently, PET was
                      performed in glioma (69/74, $93.2\%),$ followed by brain
                      metastasis (58/74, $78.4\%),$ meningioma (52/74, $70.3\%),$
                      and CNS lymphoma (46/74, $62.2\%).$ Amino acid PET was used
                      at 62/71 centers $(87.3\%),$ mainly in glioma (58/59,
                      $98.3\%)$ and for differentiation of tumor progression from
                      treatment-related changes (58/59, $98.3\%),$ differential
                      diagnosis (54/59, $91.5\%),$ and hotspot delineation (47/59,
                      $79.7\%).$ Somatostatin receptor (SSTR) PET was performed at
                      50/68 sites $(73.5\%),$ predominantly in meningioma (48/49,
                      $98.0\%),$ and for patient selection before radioligand
                      therapy (41/49, $83.7\%)$ as well as for target volume
                      definition in radiotherapy (33/49, $67.3\%)$ and
                      differential diagnosis (27/49, $55.1\%).$ PET was covered by
                      statutory health insurance at 46/59 $(78.0\%)$ centers for
                      amino acid PET and 33/49 $(67.3\%)$ for SSTR PET according
                      to self-reported information. Main reasons for not
                      performing PET in clinical routine included limited
                      availability of tracers (14/29, $48.3\%),$ high cost (11/29,
                      $37.9\%),$ and PET considered unnecessary by referring
                      physicians (8/29, $27.6\%).CONCLUSIONPET$ is widely used
                      among EORTC-BTG sites, although implementation varies and is
                      influenced by factors such as tracer availability, cost, and
                      institutional perceptions. While further data from broader
                      surveys including non-academic institutions is needed, the
                      findings support the implementation of PET as clinical trial
                      endpoint.},
      month         = {Nov},
      date          = {2025-11-20},
      organization  = {7th Quadrennial Meeting of the World
                       Federation of Neuro-Oncology Societies,
                       Honolulu (USA), 20 Nov 2025 - 23 Nov
                       2025},
      cin          = {INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)1},
      doi          = {10.1093/neuonc/noaf201.1161},
      url          = {https://juser.fz-juelich.de/record/1053910},
}